Positive inclisiran results in persistent lowering of LDL cholesterol

20 May 2019
the-medicines-company-big

The Medicines Company (Nasdaq: MDCO) on Saturday announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300mg resulted in consistent lowering of low density lipoprotein cholesterol (LDL-C) by more than 50% with overall follow-up of up to three years.

Inclisiran, the company’s lead developmental compound, was well tolerated, and no material safety issues were observed in the study. These results were presented during a late-breaking clinical trial session at the National Lipid Association (NLA) Scientific Sessions in Miami.

Inclisiran, the first cholesterol-lowering therapy in the siRNA class, is in Phase III clinical development to evaluate its ability to lower LDL-C through twice-a-year dosing. Pivotal Phase III readouts for inclisiran are expected in the third quarter. ORION-3 (n=382) is an open-label extension study of the Phase II ORION-1 trial to assess the efficacy, safety and tolerability of long-term dosing of inclisiran.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical